Lilly Tops Biopharma Innovation Survey For First Time
New Entrants Include Seagen And Inctye
Executive Summary
Conducting sector survey for a tenth year, Idea Pharma’s Mike Rea said: “COVID-19 showed companies with more agile decision-making were more likely to succeed.”
You may also be interested in...
Pandemic Perspectives: COVID-19 Upended Drug Launches In Ways That Will Stick
Preliminary data from IQVIA suggest 2020 was one of the weakest in recent years for new launch trajectories although drug companies tell Scrip there are some lessons learned from promoting during the pandemic.
As Seagen Matures, CEO Siegall Talks About Moving The Growth Goalposts
The ADC specialist could have a fourth cancer drug on the market this year and is preparing for its first commercial launch in Europe.
Roche Looks To Muscle Into Obesity Market With $2.7bn Carmot Buyout
The Swiss pharma sees the acquisition as the ‘backbone’ for its future cardiometabolic portfolio, which could include a combination with a muscle-building therapy.